Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents.

Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG

Diabetes care26 Jun 2007Cited by 62 (Europe PMC)

PMID17595353DOI10.2337/dc06-2532PepBankPUB-17595353

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, fewer maintained glycemic control after substituting exenatide than after continuing insulin.
In plain wordsFewer adults maintained blood sugar control after changing to exenatide than after continuing insulin.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseMaintenance of glycemic control
Study
n = 45
Comparator
Continued insulin
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Measurements
Maintained control
62%
exenatide
Maintained control
81%
insulin
Source sentences
Summary
A total of 62% (18 of 29) of the exenatide-treated patients maintained glycemic control compared with 81% (13 of 16) of the insulin-treated patients.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 49 patients (aged 53 +/- 8 years, with BMI 34 +/- 4 kg/m2, A1C 8.1 +/- 1.1%, and duration of diabetes 11 +/- 7 years) were randomized to either substitute exenatide for insulin or remain on their current insulin regimen.
Report a problemFND-1759535301
02HumanRandomized controlled trialSafety outcome
In exenatide-treated adults, some discontinued before week 16 because of lost glucose control.
In plain wordsSome adults stopped exenatide early because blood sugar control deteriorated.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableDiscontinuation for loss of control
Study
n = 29
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Measurements
Discontinuations
5 patients
loss of glucose control
Source sentences
Summary
Of the 11 exenatide-treated patients who did not maintain control, 5 discontinued before week 16 because of loss of glucose control.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 49 patients (aged 53 +/- 8 years, with BMI 34 +/- 4 kg/m2, A1C 8.1 +/- 1.1%, and duration of diabetes 11 +/- 7 years) were randomized to either substitute exenatide for insulin or remain on their current insulin regimen.
Report a problemFND-1759535302
03HumanRandomized controlled trialSafety outcome
In adults switching from insulin, exenatide safety was generally consistent with previous trials.
In plain wordsThe reported exenatide safety profile resembled earlier trials.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableOverall safety profile
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
The overall safety profile was generally consistent with previous exenatide trials.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 49 patients (aged 53 +/- 8 years, with BMI 34 +/- 4 kg/m2, A1C 8.1 +/- 1.1%, and duration of diabetes 11 +/- 7 years) were randomized to either substitute exenatide for insulin or remain on their current insulin regimen.
Report a problemFND-1759535303
04HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, reported hypoglycemia rates were higher with exenatide substitution than continued insulin.
In plain wordsReported low blood sugar rates were higher after changing to exenatide than after continuing insulin.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHypoglycemia rate
Study
n: not reported in source
Comparator
Continued insulin
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Measurements
Hypoglycemia rate
1.72 events/patient-year
exenatide
Hypoglycemia rate
0.97 events/patient-year
insulin
Source sentences
Summary
The mean overall hypoglycemia rates were 1.72 and 0.97 events/patient-year for the exenatide and insulin reference groups, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 49 patients (aged 53 +/- 8 years, with BMI 34 +/- 4 kg/m2, A1C 8.1 +/- 1.1%, and duration of diabetes 11 +/- 7 years) were randomized to either substitute exenatide for insulin or remain on their current insulin regimen.
Report a problemFND-1759535304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT00099333

Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents

AstraZenecan = 49Feb 2004 to Aug 2005

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 23 Feb 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.